Compare · CGON vs RVMD
CGON vs RVMD
Side-by-side comparison of CG Oncology Inc. (CGON) and Revolution Medicines Inc. (RVMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CGON and RVMD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- RVMD is the larger of the two at $45.31B, about 6.5x CGON ($7.00B).
- RVMD has been more active in the news (11 items in the past 4 weeks vs 7 for CGON).
- RVMD has more recent analyst coverage (25 ratings vs 16 for CGON).
- Company
- CG Oncology Inc.
- Revolution Medicines Inc.
- Price
- -
- -
- Market cap
- $7.00B
- $45.31B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2024
- 2020
- News (4w)
- 7
- 11
- Recent ratings
- 16
- 25
Revolution Medicines Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.
Latest CGON
- Director Post Leonard E sold $74,540 worth of shares (1,000 units at $74.54) as part of a pre-agreed trading plan and exercised 1,000 shares at a strike of $0.60 (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by CG Oncology Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by CG Oncology Inc.
- SEC Form 10-Q filed by CG Oncology Inc.
- CG Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates
- SEC Form 424B5 filed by CG Oncology Inc.
- CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet Oncology
- Director Post Leonard E exercised 1,000 shares at a strike of $0.60 and sold $71,170 worth of shares (1,000 units at $71.17) as part of a pre-agreed trading plan (SEC Form 4)
- Director Mulay James exercised 24,165 shares at a strike of $26.63 and sold $1,816,241 worth of shares (24,165 units at $75.16) as part of a pre-agreed trading plan (SEC Form 4)
Latest RVMD
- General Counsel Cislini Jeff exercised 56,280 shares at a strike of $20.00 and sold $11,904,247 worth of shares (56,894 units at $209.24) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 55,907 units (SEC Form 4)
- Officer Goldsmith Mark A exercised 80,000 shares at a strike of $4.73 and sold $17,991,107 worth of shares (86,000 units at $209.20) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Revolution Medicines Inc.
- SEC Form 144 filed by Revolution Medicines Inc.
- SEC Form 144 filed by Revolution Medicines Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Revolution Medicines Inc.
- SEC Form SCHEDULE 13G filed by Revolution Medicines Inc.
- BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration
- SEC Form 10-Q filed by Revolution Medicines Inc.
- Revolution Medicines Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits